Engineered immune cells with an emergency brake tested in lymphoma

NCT ID NCT03696784

Ongoing Disease control Sponsor: UNC Lineberger Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This early-phase study tests a new type of CAR T-cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. The cells are engineered to target and kill cancer cells, but also include a safety switch that can be activated to reduce severe side effects. The main goal is to see if the treatment is safe and to find the best dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: iC9-CAR19 T cells (engineered immune cells with a safety switch)
What this could lead to: If it works, this could point toward a safer way to use CAR T-cell therapy for B-cell lymphoma, with a built-in off switch to manage severe side effects.
What could go wrong: This is a very early phase 1 trial with only 19 participants, so it is too small to prove effectiveness. The treatment can still cause serious side effects like cytokine release syndrome, and the safety switch may not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia B-cell neoplasm B-cell non-Hodgkin lymphoma chronic lymphocytic leukemia/small lymphocytic lymphoma cytokine release syndrome immune system disorder immunoproliferative disorder lymphatic system disorder lymphoma primary central nervous system lymphoma toxic encephalopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNE SYSTEM DISEASES IMMUNOPROLIFERATIVE DISORDERS LYMPHATIC DISEASES LYMPHOMA LYMPHOMA, B-CELL

Contacts and locations

Locations

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill

Chapel Hill, North Carolina, 27599, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.